We are a medical technology company focused on developing and marketing products to collect cancer cells for molecular diagnostics by others and as cancer therapy, both of which are based on the principle of removing blood-borne circulating tumor cells (CTCs). These CTCs detach from solid tumors and enter the bloodstream carrying the DNA of the tumor and seeding new tumors. CTCs are rare and difficult to distinguish from other blood cells. However, we believe our technology is substantially more effective, both in a sensitivity and specificity context, at removing CTCs when compared to other available CTC capture technologies. We are seeking to commercialize two products which utilize our proprietary CTC removal technology:
Company profile
Ticker
VIAT
Exchange
CEO
Ilan K. Reich
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-15D
Suspension of duty to report
27 Dec 16
10-Q
2016 Q3
Quarterly report
14 Nov 16
10-Q
2016 Q2
Quarterly report
18 Aug 16
NT 10-Q
Notice of late quarterly filing
16 Aug 16
8-K
Viatar CTC Solutions Announces the Appointment of Four Directors to the Board of Directors
23 May 16
10-K/A
2015 FY
Annual report (amended)
10 May 16
10-Q
2016 Q1
Quarterly report
6 May 16
10-K
2015 FY
Annual report
28 Mar 16
D
$4.2M in equity, sold $4.2M, 4 investors
14 Mar 16
8-K
Viatar CTC Solutions Announces $4.2 Million Series B Financing
1 Mar 16
Latest ownership filings
No filings